Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 20:20:00 EET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom